Compare · CTKB vs RVTY
CTKB vs RVTY
Side-by-side comparison of Cytek Biosciences Inc. (CTKB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTKB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 24.5x CTKB ($703.2M).
- Over the past year, CTKB is up 30.2% and RVTY is up 60.0% - RVTY leads by 29.8 points.
- RVTY has been more active in the news (5 items in the past 4 weeks vs 1 for CTKB).
- RVTY has more recent analyst coverage (23 ratings vs 13 for CTKB).
PerformanceCTKB+30.20%RVTY+60.03%
2025-10-20+0.00%2026-10-16
- Company
- Cytek Biosciences Inc.
- Revvity Inc.
- Price
- $5.26-2.77%
- $152.62-1.34%
- Market cap
- $703.2M
- $17.26B
- 1M return
- +1.15%
- +4.01%
- 1Y return
- +30.20%
- +60.03%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 5
- Recent ratings
- 13
- 23
Latest CTKB
- SEC Form 8-K filed by Cytek Biosciences Inc.
- Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
- Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
- Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Cytek Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
- PRESIDENT AND CEO Jiang Wenbin converted options into 120,095 shares and covered exercise/tax liability with 36,269 shares, increasing direct ownership by 2% to 5,561,029 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mccombe William D. converted options into 35,420 shares and covered exercise/tax liability with 11,904 shares, increasing direct ownership by 21% to 134,693 units (SEC Form 4) to satisfy withholding tax
- Director Muir Glenn P converted options into 3,086 shares (SEC Form 4)
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery